Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135688 | 1.00 | PREP (0.42) | PREPALDH1A1HSD11B1CCR5CYP3A4 | |
| SCHEMBL16898055 | 0.78 | ALDH1A1 (0.43) | PREPALDH1A1 | |
| SCHEMBL16898052 | 0.78 | ALDH1A1 (0.43) | PREPALDH1A1 | |
| SCHEMBL7424831 | 0.76 | NPC1 (0.46) | CCR5CYP2C19 | |
| SCHEMBL4317709 | 0.76 | ALDH1A1 (0.44) | PREPALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7047076 | 0.76 | ALOX15 (0.45) | PREPALDH1A1 | |
| SCHEMBL7047075 | 0.76 | ALOX15 (0.45) | PREPALDH1A1 | |
| SCHEMBL4314804 | 0.76 | ALDH1A1 (0.44) | PREPALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6474715 | 0.76 | ALDH1A1 (0.44) | PREPALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL134600 | 0.75 | ALDH1A1 (0.43) | PREPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013082388-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-6908911-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
| EP-1210330-B1 | ANTIBACTERIAL AGENTS | VERNALIS OXFORD LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| WO-2000061134-A9 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2004-04-22 | — | — | WO | disclosed |
| US-6716878-B1 | BACTERICIDE, ANTIPROTOZOAL; VANCOMYCIN RESISTANT ENTEROCOCCI AND BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA, METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; HYDROXAMIC ACID AND N-FORMYL SUBTITUTED ALKYLAMIDES | VERNALIS (OXFORD) LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-1169031-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, HAMP | PREP 6/4885ALDH1A1 2465/4885HSD11B1 2563/4885 |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | PREP 4/4885ALDH1A1 985/4885HSD11B1 2118/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | PREP 9/4885ALDH1A1 1567/4885HSD11B1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.